Zobrazeno 1 - 10
of 59
pro vyhledávání: '"MICHAEL R. HODGES"'
Autor:
Jose A. Vazquez, Peter G. Pappas, Kenneth Boffard, Fathima Paruk, Paul A. Bien, Margaret Tawadrous, Eric Ople, Pamela Wedel, Iwona Oborska, Michael R. Hodges
Publikováno v:
Antimicrobial Agents and Chemotherapy. 67
Fosmanogepix (FMGX), a novel antifungal available in intravenous (IV) and oral formulations, has broad-spectrum activity against pathogenic yeasts and molds, including fungi resistant to standard of care antifungals. This multicenter, open-label, sin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2ce20deecf8332969d2c1f25c93d2526
https://doi.org/10.1128/aac.01419-22
https://doi.org/10.1128/aac.01419-22
Autor:
Michael R. Hodges, Eric Ople, Pamela Wedel, Karen J. Shaw, Abhijeet Jakate, William G. Kramer, Sjoerd van Marle, Ewoud-Jan van Hoogdalem, Margaret Tawadrous
Publikováno v:
Antimicrobial Agents and Chemotherapy. 67
Fosmanogepix (FMGX, APX001), a first-in-class, intravenous (i.v.) and oral (p.o.) antifungal prodrug candidate is currently in clinical development for the treatment of invasive fungal infections. Manogepix (MGX, APX001A), the active moiety of FMGX,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8519ae4f2f641b726b374191c2ec7bea
https://doi.org/10.1128/aac.01623-22
https://doi.org/10.1128/aac.01623-22
Autor:
Yuliya Yasinskaya, Shukal Bala, Ursula Waack, Cheryl Dixon, Karen Higgins, Jason N Moore, Caroline J Jjingo, Elizabeth O'Shaughnessy, Philip Colangelo, Radu Botgros, Sumathi Nambiar, David Angulo, Aaron Dane, Tom Chiller, Michael R Hodges, Taylor Sandison, William Hope, Thomas J Walsh, Peter Pappas, Aspasia Katragkou, Laura Kovanda, John H Rex, Kieren A Marr, Luis Ostrosky-Zeichner, Shohko Sekine, Monika Deshpande, Sunita J Shukla, John Farley
Publikováno v:
Clinical Infectious Diseases.
Pressing challenges in the treatment of invasive fungal infections (IFIs) include emerging and rare pathogens, resistant/refractory infections, and antifungal armamentarium limited by toxicity, drug-drug interactions, and lack of oral formulations. D
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::13aeec0d6978925d410973556a32de81
https://doi.org/10.1093/cid/ciad195
https://doi.org/10.1093/cid/ciad195
Autor:
Thomas J. Walsh, Robert Mansbach, Ruta Petraitiene, Bo Bo Win Maung, Michael R. Hodges, Karen Joy Shaw, Vidmantas Petraitis, Malcolm Finkelman
Publikováno v:
Antimicrob Agents Chemother
Candida endophthalmitis is a serious sight-threatening complication of candidemia that may occur before or during antifungal therapy. Hematogenous Candida meningoencephalitis (HCME) is also a serious manifestation of disseminated candidiasis in prema
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::21bb964b29658ddcf17eebcfa92f2f3e
https://doi.org/10.1128/aac.01795-20
https://doi.org/10.1128/aac.01795-20
Autor:
Lucy S. Jun, Nanda Balasubramanian, Lin Lin, Susan Sobolov, Xiang Gao, Bjorn L. Miliard, Jian-Ping Tang, Melissa A. Lasaro, Michael R. Hodges, John M. Burke, Joshua F. Apgar, Kevin J. Moore, Anna Katharina Wilkins, Pratap Singh
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology. 7:404-412
Crigler-Najjar syndrome type 1 (CN1) is an autosomal recessive disease caused by a marked decrease in uridine-diphosphate-glucuronosyltransferase (UGT1A1) enzyme activity. Delivery of hUGT1A1-modRNA (a modified messenger RNA encoding for UGT1A1) as a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8e596ac0f011b45481ac39b69d38242d
https://doi.org/10.1002/psp4.12301
https://doi.org/10.1002/psp4.12301
Autor:
Joshua F, Apgar, Jian-Ping, Tang, Pratap, Singh, Nanda, Balasubramanian, John, Burke, Michael R, Hodges, Melissa A, Lasaro, Lin, Lin, Bjorn L, Millard, Kristi, Moore, Lucy S, Jun, Susan, Sobolov, Anna Katharina, Wilkins, Xiang, Gao
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology
Crigler‐Najjar syndrome type 1 (CN1) is an autosomal recessive disease caused by a marked decrease in uridine‐diphosphate‐glucuronosyltransferase (UGT1A1) enzyme activity. Delivery of hUGT1A1‐modRNA (a modified messenger RNA encoding for UGT1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::b6259f975f70e47c83e009e9a153a9d8
http://europepmc.org/articles/PMC6391595
http://europepmc.org/articles/PMC6391595
Autor:
Galia Rahav, Jose A. Vazquez, Mickael Aoun, Pierre Bulpa, Bart Jan Kullberg, Sara Barbat, Todd P McCarty, Ilana Oren, Ricard Ferrer, Michael R. Hodges, George Richard Thompson, Peter G. Pappas, Haran T. Schlamm, Pamela Wedel, Ronen Ben-Ami, Iwonka Oborska
Publikováno v:
Open Forum Infectious Diseases
Background Fosmanogepix (FMGX) is a first-in-class antifungal agent, with a unique MOA targeting the fungal enzyme Gwt1, that has broad-spectrum activity against both yeasts, molds, and dimorphic fungi, including fungi resistant to other antifungal a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::01d0a15fd8e2c671a24b159bb88875fd
https://doi.org/10.1093/ofid/ofaa439.457
https://doi.org/10.1093/ofid/ofaa439.457
Autor:
Michael R. Hodges
Publikováno v:
The G8’s Role in the New Millennium ISBN: 9780429435799
The G8’s Role in the New Millennium
The G8’s Role in the New Millennium
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9f5363a0ceb1c0d794d4bad9a681fbff
https://doi.org/10.4324/9780429435799-4
https://doi.org/10.4324/9780429435799-4
Part 1 Explaining G8 effectiveness: continuity and leadership in an age of globalization, Sir Nicholas Bayne explaining G8 effectiveness, John J. Kirton the G8 and the new political economy, Michael R. Hodges G8 summits and compliance, Ella Kokotsis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fdd5faef2e60d06f9241db2ef6181c5c
https://doi.org/10.4324/9780429435799
https://doi.org/10.4324/9780429435799
Autor:
Bart Jan Kullberg, Michael R. Hodges, Ilana Oren, George Richard Thompson, Peter G. Pappas, Sara Barbat, Pierre Bulpa, Mickael Aoun, Pamela Wedel, Haran T. Schlamm, Galia Rahav, Jose A. Vazquez
Publikováno v:
Open Forum Infectious Diseases
Background Fosmanogepix (FMGX) is a first-in-class antifungal agent, with a unique MOA targeting the fungal enzyme Gwt1, and broad-spectrum activity against yeasts and molds, including fungi resistant to other antifungal agents. Patients with candide
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8983bd4c273ff0727cc98090d5d31146
http://europepmc.org/articles/PMC7776851
http://europepmc.org/articles/PMC7776851